VALN
ValnevaVALN
VALN
About: Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Employees: 713
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
20% more funds holding
Funds holding: 10 [Q3] → 12 (+2) [Q4]
0% more ownership
Funds ownership: 0.44% [Q3] → 0.44% (+0%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
27% less capital invested
Capital invested by funds: $4.35M [Q3] → $3.16M (-$1.19M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
116%
upside
Avg. target
$15.33
137%
upside
High target
$17
163%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Vamil Divan 39% 1-year accuracy 12 / 31 met price target | 116%upside $14 | Buy Maintained | 8 May 2025 |
HC Wainwright & Co. Edward White 16% 1-year accuracy 22 / 135 met price target | 163%upside $17 | Buy Reiterated | 15 Apr 2025 |
Guggenheim Dana Flanders 0% 1-year accuracy 0 / 1 met price target | 132%upside $15 | Buy Maintained | 24 Mar 2025 |
Financial journalist opinion
Based on 22 articles about VALN published over the past 30 days
Neutral
GlobeNewsWire
3 hours ago
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
Saint Herblain (France), May, 12 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC), in a joint communication to the medical community, have recommended a pause in the use of Valneva's single-dose live attenuated chikungunya vaccine IXCHIQ® in elderly individuals while ongoing investigations into reported serious adverse events (SAEs) are completed. This update follows an earlier recommendation from the U.S. Advisory Committee on Immunization Practices (ACIP) to include a precaution related to the use of IXCHIQ® in persons aged 65 and over and a similar decision by the European Medicines Agency (EMA) to temporarily suspend the use of the vaccine for individuals over 65 years old pending investigation.
Neutral
Seeking Alpha
2 days ago
Valneva SE (VALN) Q1 2025 Earnings Call Transcript
Valneva SE (NASDAQ:VALN ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Joshua Drumm - Vice President-Global Investor Relations Thomas Lingelbach - Chief Executive Officer Peter Bühler - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Rajan Sharma - Goldman Sachs Vamil Divan - Guggenheim Securities. Samir Devani - Rx Securities Oscar Haffen Lamm - Bryan, Garnier & Co. Simon Scholes - First Berlin Joshua Drumm Thank you.
Positive
Seeking Alpha
4 days ago
Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance
Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Ixiaro generated roughly €94.1 million in 2024 and remains Valneva's main revenue vertical. Dukoral contributed with €32.3 million in sales in 2024 and provides some revenue diversification alongside Ixiaro in the traveler-vaccine niche.
Neutral
GlobeNewsWire
4 days ago
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
Saint Herblain (France), May, 07 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva's single-dose live attenuated chikungunya vaccine IXCHIQ® based on reports of serious adverse events (SAEs) in elderly people. As a temporary measure, while this review is ongoing, EMA has suspended the use of the vaccine for individuals over 65 years old. EMA has maintained current recommendations for IXCHIQ® for people from 12 to 64 years of age.
Negative
Reuters
4 days ago
Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people
The European Union's health regulator said on Wednesday it has begun a review of Valneva's chikungunya vaccine after reports of serious adverse events in older adults, including two deaths globally.
Neutral
GlobeNewsWire
5 days ago
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Saint-Herblain (France), May 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its 2025 financial guidance. The condensed consolidated interim financial results are available on the Company's website (Financial Reports – Valneva).
Neutral
GlobeNewsWire
2 weeks ago
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France's national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing vaccination campaign in La Reunion and Mayotte. Valneva has been responding to the French government's call for vaccine supply of IXCHIQ® in La Reunion1 as the island is going through a major chikungunya outbreak with ~ 40,000 confirmed cases since the beginning of 20252.
Neutral
GlobeNewsWire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Neutral
Accesswire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ:VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
NEW YORK CITY, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ:VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Charts implemented using Lightweight Charts™